特瑞普利单抗联合化疗一线治疗广泛期小细胞肺癌:3期EXTENTORCH随机临床试验
这项多中心、双盲、安慰剂对照3期随机临床试验(EXTENTORCH)在中国49个中心纳入442例广泛期小细胞肺癌患者,评估特瑞普利单抗联合依托泊苷铂类化疗(EP)对比安慰剂联合EP一线治疗。特瑞普利单抗组较安慰剂组显著改善研究者评估的无进展生存期(HR 0.67,95%CI 0.54-0.82;P<.001),并显著降低死亡风险(HR 0.80,95%CI 0.65-0.98;P=.03)。两组≥3级治疗中出现的不良事件发生率相似。
要点
- 特瑞普利单抗联合EP一线治疗广泛期小细胞肺癌显著改善无进展生存期(HR 0.67)和总生存期(HR 0.80)。
- 中位总生存期特瑞普利单抗组14.6个月 vs 安慰剂组13.3个月。
- ≥3级治疗中出现的不良事件发生率特瑞普利单抗组89.6% vs 安慰剂组89.4%,未见新安全性信号。
核心结论
- 在3期随机临床试验中,一线化疗联合特瑞普利单抗显著改善广泛期小细胞肺癌患者的无进展生存期和总生存期,安全性可接受,支持该联合方案作为新的治疗选择。
研究设计与样本
- 多中心、双盲、安慰剂对照3期随机临床试验(EXTENTORCH),于2019年9月26日至2021年5月20日在中国49个中心入组患者。
- 共筛查595例患者,随机分配442例 eligible 患者(中位[范围]年龄63[30-77]岁;366例[82.8%]男性),特瑞普利单抗联合EP组223例,安慰剂联合EP组219例。
- 患者按1:1随机接受特瑞普利单抗240 mg或安慰剂联合EP,每3周一次,最多4至6个周期,随后特瑞普利单抗或安慰剂维持治疗直至疾病进展、不可耐受的毒性或最多2年。
- 主要终点为研究者评估的无进展生存期和总生存期;对300例患者进行全外显子组测序以识别疗效相关生物标志物。
- 数据于2023年5月6日至2024年6月1日期间分析。
主要发现
- 截至2023年4月20日,中位(范围)生存随访时间为13.7(0.0-42.7)个月。
- 特瑞普利单抗组较安慰剂组显著改善研究者评估的无进展生存期(HR 0.67,95%CI 0.54-0.82;P<.001),并显著降低死亡风险(HR 0.80,95%CI 0.65-0.98;P=.03)。
- 中位总生存期特瑞普利单抗组为14.6个月(95%CI 12.9-16.6),安慰剂组为13.3个月(95%CI 11.8-14.4)。
- 300例患者的全外显子组测序结果显示,低肿瘤内异质性、HLA-A11+ HLA-B62-单倍型、野生型KMT2D和COL4A4、或CTNNA2或SCN4A序列变异与特瑞普利单抗组有利的无进展生存期和总生存期相关。
- 未观察到新的安全性信号;≥3级治疗中出现的不良事件发生率在特瑞普利单抗组和安慰剂组安全性人群中相似(特瑞普利单抗组199/222例[89.6%] vs 安慰剂组193/216例[89.4%])。
关键数值与推荐
- 特瑞普利单抗240 mg或安慰剂联合EP,每3周一次,最多4至6个周期,后续维持治疗直至疾病进展、不可耐受毒性或最多2年。
- 主要终点为研究者评估的无进展生存期和总生存期。
- 特瑞普利单抗组较安慰剂组无进展生存期HR 0.67(95%CI 0.54-0.82;P<.001),总生存期HR 0.80(95%CI 0.65-0.98;P=.03)。
临床怎么用
- 作者认为,特瑞普利单抗联合一线化疗可作为广泛期小细胞肺癌患者的新治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with extensive-stage small cell lung cancer (ES-SCLC) have poor prognoses and unmet medical needs. OBJECTIVE: To evaluate the efficacy and safety of toripalimab plus etoposide and platinum-based chemotherapy (EP) vs placebo plus EP as a first-line treatment for patients with ES-SCLC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial (EXTENTORCH study) enrolled patients from September 26, 2019, to May 20, 2021, and was conducted at 49 sites in China. Eligible patients had histologically or cytologically confirmed ES-SCLC without previous systemic antitumor therapy for ES-SCLC. Data were analyzed between May 6, 2023, and June 1, 2024. INTERVENTIONS: Patients were randomized (1:1) to receive toripalimab, 240 mg, or placebo plus EP every 3 weeks for up to 4 to 6 cycles, followed by maintenance with toripalimab or placebo until disease progression, intolerable toxic effects, or up to 2 years of treatment. MAIN OUTCOMES AND MEASURES: The primary end points were investigator-assessed progression-free survival (PFS) and overall survival (OS). Whole-exome sequencing results identified correlative biomarkers for clinical efficacy. RESULTS: Among 595 screened patients, 442 eligible patients were randomized (median [range] age, 63 [30-77] years; 366 [82.8%] male); 223 patients were randomized to toripalimab plus EP, and 219 to placebo plus EP. By April 20, 2023, the median (range) survival follow-up was 13.7 (0.0-42.7) months. Compared with placebo, toripalimab improved investigator-assessed PFS (hazard ratio [HR], 0.67 [95% CI, 0.54-0.82]; P < .001), and significantly reduced the risk of death (HR, 0.80 [95% CI, 0.65-0.98]; P = .03). The median OS was 14.6 (95% CI, 12.9-16.6) months in the toripalimab group vs 13.3 (95% CI, 11.8-14.4) months in the placebo group. Whole-exome sequencing results from 300 patients identified low intratumor heterogeneity, HLA-A11+ HLA-B62- haplotype, wild-type KMT2D and COL4A4, or sequence variations in CTNNA2 or SCN4A correlated with favorable PFS and OS in the toripalimab group. No new safety signals were observed. Grade 3 or higher treatment-emergent adverse event incidence was similar between the toripalimab and placebo safety set groups (199 of 222 patients [89.6%] vs 193 of 216 patients [89.4%], respectively). CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, adding toripalimab to first-line chemotherapy demonstrated significant improvements in PFS and OS for patients with ES-SCLC. The treatment exhibited an acceptable safety profile, supporting this combination regimen as a new treatment option for patients with ES-SCLC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04012606.
引用
- Cheng Y, Zhang W, Wu L, et al. Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 39541202. doi:10.1001/jamaoncol.2024.5019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。